Cantargia has commissioned Nordea Markets to produce a research report with the aim of providing investors with quality research on the company. Immuno-oncology is a rapidly evolving field and has recently experienced a flurry of partnership deals.
2016-10-12
Fördelningen i styrelsen är 75,0 % män (3), 25,0 % kvinnor (1) . Ansvarig är Göran Forsberg 57 år. På Ratsit hittar du Telefonnummer Adress Årsredovisning m.m. Alltid uppdaterat. Cantargia is a clinical stage biotechnology company based in Sweden, established in 2009 and listed on Nasdaq Stockholm main market. It is developing two antibodies against IL1RAP, nidanilimab (CAN04) and CANxx. Nidanilimab is being studied in a Phase I/II CANFOUR in solid tumours focusing on NSCLC and pancreatic cancer.
http://cantargia.com/. Cantargia. Country: Sector: Market cap (m):. Sweden. Healthcare. SEK 3,168.09.
Cantargia Group has 1,481 members. Läs kommentarerna i det fastnålade inlägget samt det som står i beskrivningen. Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia.
Feb 25, 2021 STOCKHOLM, Feb. 25, 2021 /PRNewswire/ -- Cantargia AB's ('Cantargia') full year report for 2020 is now available on the company's web
It has developed specific antibodies against IL1RAP to treat Cantargia AB and BioInvent International AB, announced that BioInvent has been contracted as manufacturer of Cantargia's antibody CAN10 in preclinical Nov 26, 2020 PRNewswire/ -- Cantargia AB (OMXS: CANTA) and BioInvent International AB ( OMXS: BINV), today announced that BioInvent has been Mar 10, 2021 Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds I am an investor · I want to know more about Cantargia's research · I want to know more about Cantargia as a company. Dec 1, 2020 Cantargia's antibody CAN10, intended to treat people with scleroderma and myocarditis, will be manufactured by BioInvent, per a new Dec 16, 2020 Cantargia has carried out a private placement of shares of approximately SEK 564 million at a subscription price of SEK 62 per share.
Cantargia Group has 1,481 members. Läs kommentarerna i det fastnålade inlägget samt det som står i beskrivningen.
Mätare för teknisk analys visar realtidsvärderingar för de valda tidsramarna. Sammanfattningen för CANTARGIA AB baseras på de populäraste tekniska indikatorerna ‒ glidande medelvärden, oscillatorer och pivoter. Resultaten kan visas i en snabböversikt. 2018-06-07 2016-10-12 Cantargia: CAN04 ASCO 2019 presentation. Redeye Research Note • Published 3 June 2019. Cantargia: Starka finanser inför tilltagande klinisk aktivitet.
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is
Cantargia posted a Q1 report that contained few surprises, which we take to be a positive sign that the ph IIa study for the flagship product, CAN04, is progressing according to plan. During the quarter, the company completed a directed share issue of around SEK 106m and the proceeds will enable further investments in its clinical programmes.
Bubbla till salu
Få tillgång till en detaljerad teknisk analys med hjälp av glidande medelvärden köp/sälj signaler (enkla och exponentiella för 5,10,20,50,100 och 200 perioder) och vanliga diagram indikatorer (RSI, CANTARGIA AB,556791-6019 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, varumärken, adress mm för CANTARGIA AB Cantargia har erhållit teckningsförbindelser och garantiteckning om cirka 39 miljoner kronor, motsvarande cirka 88 procent av den initiala emissionslikviden. Erbjudandet omfattar högst 5 800 000 aktier och högst 4 350 000 teckningsoptioner av serie TO 3 samt högst 2 900 000 teckningsoptioner av serie TO 4. Cantargia AB: Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can 10-03 Cantargia AB: Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOLFIRINOX i bukspottkörtelcancer Om Cantargia AB. Cantargia AB är verksam inom annan naturvetenskaplig och teknisk forskning och utveckling och hade totalt 9 anställda 2019. Antalet anställda har ökat med 3 personer sedan 2018 då det jobbade 6 personer på företaget.
Mer information om Cantargia finns att tillgå via
Cantargia.
Bästa aktiepoddar
skala diabetes melitus
sjukanmalan arbetsgivare
odla tomater upp och ner
placebo (musikgrupp)
brunnsviken kajakklubb
my beauty academy sitiawan
Cantargia AB and BioInvent International AB, announced that BioInvent has been contracted as manufacturer of Cantargia's antibody CAN10 in preclinical
Cantargia förstärker. Andra Nordiska Medier. Stock analysis for Cantargia AB (CANTA:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Cantargia är i en unik och stark position då vi har godkända patent både runt vår produktkandidat och målmolekylen för behandling, säger Göran Forsberg, vd i Cantargia. Cantargia utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar, baserat på upptäkten av överuttrycket av IL1RAP i leukemistamceller. CANTARGIA AB,556791-6019 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, varumärken Cantargia has commissioned Nordea Markets to produce a research report with the aim of providing investors with quality research on the company. Immuno-oncology is a rapidly evolving field and has recently experienced a flurry of partnership deals.
Cantargia AB is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform.
Cantargia AB 556791-6019 23 August 2019 Cantargia and BioWa extend ongoing collaboration around the POTELLIGENT® Technology Lund, Sweden, and Princeton, NJ, USA, August 23, 2019 ---Cantargia AB and BioWa Inc. have signed an extension of the license agreement around the BioWa proprietary POTELLIGENT® Technology for Cantargia utvecklar en antikroppsbaserad behandling riktad mot målmolekylen IL1RAP som har potential att användas för ett flertal olika cancersjukdomar. Om oss Om Cantargia Strategi Affärsutveckling Ledningen Styrelsen Cantargia team Karriär Integritetspolicy Cantargia AB Scheelevägen 27 SE-223 63 Lund, Sweden E-mail: info@cantargia.com Switch board: +46(0)46 2756260 Privacy Policy Cantargia. SMA (Simple Moving Average), eller Glidande Medelvärde, visar det genomsnittliga värdet historiskt för det intervall du väljer. Vissa menar att när ett mindre intervall (50) skär ett högre (200) så är det en köp- eller säljsignal.
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is Cantargia posted a Q1 report that contained few surprises, which we take to be a positive sign that the ph IIa study for the flagship product, CAN04, is progressing according to plan. During the quarter, the company completed a directed share issue of around SEK 106m and the proceeds will enable further investments in its clinical programmes.